Clinical trials: SARS
Coronavirus Infection, SARS-CoV 2
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults…
- Trial name
- NCT04447781
- Testing
- INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer
- Where
- 2 sites in South Korea
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
COVID-19, Coronavirus
Will Hydroxychloroquine Impede or Prevent COVID-19
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus…
- Conditions
- COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
- Trial name
- WHIP COVID-19 (NCT04341441)
- Testing
- Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Monitoring Visit - Baseline
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Influenza, SARS-CoV-2 (COVID-19) Infection
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19.
- Conditions
- Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
- Trial name
- WU 437 (NCT06848309)
- Testing
- Bronchoscopy
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19, SARS-CoV-2 Infection
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
- Trial name
- ARTEMIS-C (NCT06147063)
- Testing
- AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
- Where
- 5 sites in United States
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19, SARS-CoV-2 Pneumonia
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years…
- Trial name
- NCT05465785
- Testing
- Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and…
- Trial name
- NCT04816643
- Testing
- Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg
- Where
- 128 sites in United States, Brazil and 4 more
- Volunteers
- 11,837 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
- Trial name
- NCT04405076
- Testing
- Biological: mRNA-1273, mRNA-1273.351
- Where
- 8 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Coronavirus, Covid19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04515147
- Testing
- CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine
- Where
- 2 sites in Panama, Peru
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- CureVac
Healthy
Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
This Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers.
- Trial name
- MUCOBOOST (NCT06821126)
- Testing
- LVT-001, Cormirnaty
- Where
- 5 sites in France
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
SARS-CoV-2
Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19
This is a phase I, double-blind, placebo-controlled,dose-ranging clinical trial in healthy males and non-pregnant females, 18 to 55 years of age.
- Trial name
- NCT04844268
- Testing
- Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine, Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SENAI CIMATEC
Coronavirus Disease 2019 (COVID-19)
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells.
- Trial name
- COVID-19 (NCT04894409)
- Testing
- Mouthwash and nose rinse with the AgNPs solution, Mouthwashes and nose rinse in a conventional way
- Where
- Mexico
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Cluster de Bioeconomia de Baja California, A.C
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04799392
- Testing
- NOWDx COVID-19 Test
- Where
- 5 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
COVID-19
COVID-19 Household Transmission Study
This study will test and follow persons quarantined at home after testing positive for SARS-CoV-2 (COV) aged 18 years and older and their household members aged 1 year and older.
- Trial name
- CO-HOST (NCT04445233)
- Testing
- COVID-19 IgM-IgG Rapid Test
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Covid19, Diabetes Mellitus, Type 2
Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19
It is known that COVID-19 has a more negative clinical course and causes higher degrees of morbidity and mortality in case of COVID-19 in diabetic patients.
- Trial name
- NCT04695158
- Testing
- COVID-19 group (Group I), Type II Diabetes Mellitus and COVID-19 group (Group II)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Izmir Bakircay University
Covid19
Serological Profile of Children and Young Adolescents With at Least One COVID-19 Diagnosed Family Member
Use of rapid serological tests to assess the vulnerability to SARS-CoV-2 infection of subjects aged 4-16 years old and cohabiting with at least one family member who tested positive to SARS-CoV-2
- Trial name
- NCT04649944
- Testing
- Serological test and phone interview
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Milan
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
SARS-CoV-2
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.
- Trial name
- NCT04728347
- Testing
- ARCT-021
- Where
- Singapore
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Covid19
A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19
To investigate the safety and immunogenicity profile of of a novel and investigational SARS-CoV-2 DNA vaccine, which is delivered intramuscularly followed by electroporation to enhance vaccine penetration, as a potential…
- Trial name
- NCT05102643
- Testing
- SARS-CoV-2 DNA Vaccine
- Where
- Hong Kong
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
SARS-CoV-2
A Study of S-268019 for the Prevention of COVID-19
The main purpose of this study is to assess the efficacy of S-268019-b for the prevention of COVID-19 in the initial vaccination period prior to crossover in participants without evidence of infection before vaccination as…
- Trial name
- NCT05212948
- Testing
- S-268019-b
- Where
- Vietnam
- Volunteers
- 9,902 people, healthy volunteers welcome
- Sponsor
- Shionogi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.